Ken Griffin Alx Oncology Holdings Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 71,600 shares of ALXO stock, worth $115,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,600

Previous 34,800 105.75%

Holding current value

$115,992

Previous $209,000 37.8%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.84 - $17.56 $6.81 Million - $20.5 Million	-1,166,704 Reduced 94.45%	68,511 $413,000
Q1 2024 May 15, 2024	BUY	$10.95 - $16.79 $23,082 - $35,393	2,108 Added 0.17%	1,235,215 $13.8 Million
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $3.89 Million - $12.4 Million	807,890 Added 189.99%	1,233,107 $18.4 Million
Q3 2023 Nov 14, 2023	BUY	$4.19 - $7.35 $934,093 - $1.64 Million	222,934 Added 110.21%	425,217 $2.04 Million
Q2 2023 Aug 14, 2023	SELL	$4.37 - $9.56 $177,417 - $388,126	-40,599 Reduced 16.72%	202,283 $1.52 Million
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $458,929 - $1.19 Million	101,533 Added 71.83%	242,882 $1.1 Million
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $922,821 - $1.26 Million	-97,037 Reduced 40.71%	141,349 $1.59 Million
Q3 2022 Nov 14, 2022	BUY	$8.23 - $15.14 $1.32 Million - $2.42 Million	160,131 Added 204.63%	238,386 $2.28 Million
Q2 2022 Aug 15, 2022	SELL	$5.89 - $19.46 $328,514 - $1.09 Million	-55,775 Reduced 41.61%	78,255 $633,000
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $620,474 - $1 Million	45,456 Added 51.32%	134,030 $2.27 Million
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $110,566 - $382,788	-5,145 Reduced 5.49%	88,574 $1.9 Million
Q3 2021 Nov 15, 2021	BUY	$52.51 - $80.91 $3.74 Million - $5.76 Million	71,183 Added 315.86%	93,719 $6.92 Million
Q2 2021 Aug 16, 2021	SELL	$52.2 - $75.23 $1.91 Million - $2.76 Million	-36,677 Reduced 61.94%	22,536 $1.23 Million
Q1 2021 May 17, 2021	SELL	$62.84 - $87.68 $14.1 Million - $19.6 Million	-224,043 Reduced 79.1%	59,213 $4.37 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $9.66 Million - $31.8 Million	283,256 New	283,256 $24.4 Million

Others Institutions Holding ALXO

# of Institutions

101

Shares Held

39.7M

Call Options Held

134K

Put Options Held

17.4K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $66M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account